United States ($) USD
Austria (€) EUR
Belgium (€) EUR
Finland (€) EUR
France (€) EUR
Germany (€) EUR
Ireland (€) EUR
Japan (¥) JPY
Luxembourg (€) EUR
Netherlands (€) EUR
Switzerland (CHF) CHF
United Kingdom (£) GBP
- Regulatory Status
- RUO
- Other Names
- CD274, Programmed cell death 1 ligand 1 (PD-L1), B7 homolog 1(B7h1)
- Ave. Rating
- Submit a Review
- Product Citations
- publications
-
Immobilized recombinant human PD-L1 at 1 µg/mL binds human PD-1 in a dose-dependent manner. The ED50 for this effect is 1.5 – 9 ng/mL. -
Stability Testing for Recombinant Human PD-L1-Fc Chimera. Recombinant human PD-L1-Fc Chimera was aliquoted in PBS at 0.2 mg/mL and one aliquot was kept at 4°C (Control), and another was frozen and thawed four times (4x Freeze/Thaw). After this procedure, the samples were tested in functional ELISA. The ED50 for this effect is 1.5 – 9 ng/mL.
| Cat # | Size | Price | Save |
|---|---|---|---|
| 567704 | 25 µg | ¥58,710 | |
| 567706 | 100 µg | ¥125,370 |
PD-L1, a member of the B7 family, is a type I transmembrane protein of 290 amino acids. Human PD-L1 has 70% amino acid identity to its mouse orthologue. Binding of PD-L1 to its receptor PD-1 leads to the inhibition of T cell receptor–mediated lymphocyte proliferation and cytokine secretion. PD-L1 induces IL-10 production in T cells stimulated with low levels of anti-CD3. PD-L1/PD-1 interaction suppresses immune responses against autoantigens and tumors and plays an important role in the maintenance of peripheral immune tolerance. Disruption of the PD-L1 gene leads to up-regulated T cell responses and the generation of self-reactive T cells. Antibodies against PD-1 or PD-L1 leads to increased antitumor immunity. PD-L1 has an important role in conferring fetomaternal tolerance in an allogeneic pregnancy model. Antibodies against PD-L1 lead to a breakdown in maternal tolerance to the fetus. PD-L1 shares its receptor with PD-L2 (CD273, B7-DC). PD-L2 has a more limited expression than PD-L1, being expressed on activated macrophages and dendritic cells. PD-L1 is expressed in many tumors, and the interaction with its receptor activates signaling pathways that inhibit T-cell activity and therefore the antitumor immune response. Antibodies targeting PD-1 or PD-L1 block the PD-1 pathway and reactivate T cell activity.
Product DetailsProduct Details
- Source
- Human PD-L1, amino acid Phe19-Arg238 (Accession: #Q9NZQ7.1), with a linker (GG) and a C-terminal human IgG (Pro100-Lys330), was expressed in CHO cells.
- Molecular Mass
- The 453 amino acid recombinant protein has a predicted molecular mass of approximately 51.24 kD. The DTT-reduced and non-reduced protein shall migrate at approximately 62 -80 kD and 100 – 140 kD by SDS-PAGE, respectively. The predicted N-terminal amino acid is Phe.
- Purity
- > 95%, as determined by Coomassie-stained SDS-PAGE.
- Formulation
- 0.22 µm filtered protein solution is in PBS.
- Endotoxin Level
- Less than 0.1 EU per µg cytokine as determined by the LAL method.
- Concentration
- 25 µg size is bottled at 200 µg/mL. 100 µg size and larger sizes are lot-specific and bottled at the concentration indicated on the vial. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
- Storage & Handling
- Unopened vial can be stored between 2°C and 8°C for up to 2 weeks, at -20°C for up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin the vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 µg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to one week and stored at -20°C or colder for up to 3 months. Avoid repeated freeze/thaw cycles.
- Activity
- Immobilized recombinant human PD-L1 at 1 µg/mL binds human PD-1 in a dose-dependent manner. The ED50 for this effect is 1.5 – 9 ng/mL.
- Application
-
Bioassay
- Application Notes
-
BioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are validated in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at tech@biolegend.com.
Antigen Details
- Structure
- Dimer
- Distribution
-
APC, monocytes, dendritic cells, expressed in nonlymphoid tissues, and stromal cell
- Function
- Enhances CD28-independent T-helper cell function, suppresses immune responses against autoantigens, and participates in fetomaternal tolerance
- Interaction
- Antigen-stimulated T and B cells, regulatory T cells, follicular T and B cells, dendritic cells, and monocytes
- Ligand/Receptor
- PD-1 (CD279)
- Bioactivity
- Tested by the ability of PD-L1 to bind to its receptor PD-1
- Cell Type
- Antigen-presenting cells, Dendritic cells, Monocytes
- Biology Area
- Cell Proliferation and Viability, Immuno-Oncology, Immunology
- Molecular Family
- CD Molecules
- Antigen References
-
- Dong H, et al. 1999. Nat Med. 5:1365-9.
- Freeman GJ, et al. 2000. J Exp Med. 192:1027-34.
- Latchman Y, et al. 2001. Nat Immunol. 2:261-8.
- Latchman YE, et al. 2004. Proc Natl Acad Sci USA. 101:10691.
- Guleria I, et al. 2005. J Exp Med. 202:231-7.
- Lin DY, et al. 2008. Proc Natl Acad Sci USA. 105:3011.
- Dai S, et al. 2014. Cell Immunol. 290:72-9.
- Melero I, et al. 2015. Nat Rev Cancer. 15:457-72.
- Gene ID
- 29126 View all products for this Gene ID
- UniProt
- View information about PD-L1 on UniProt.org
Related Pages & Pathways
Pathways
Related FAQs
- Why choose BioLegend recombinant proteins?
-
• Each lot of product is quality-tested for bioactivity as indicated on the data sheet.
• Greater than 95% Purity or higher, tested on every lot of product.
• 100% Satisfaction Guarantee for quality performance, stability, and consistency.
• Ready-to-use liquid format saves time and reduces challenges associated with reconstitution.
• Bulk and customization available. Contact us.
• Learn more about our Recombinant Proteins. - How does the activity of your recombinant proteins compare to competitors?
-
We quality control each and every lot of recombinant protein. Not only do we check its bioactivity, but we also compare it against other commercially available recombinant proteins. We make sure each recombinant protein’s activity is at least as good as or better than the competition’s. In order to provide you with the best possible product, we ensure that our testing process is rigorous and thorough. If you’re curious and eager to make the switch to BioLegend recombinants, contact your sales representative today!
- What is the specific activity or ED50 of my recombinant protein?
-
The specific activity range of the protein is indicated on the product datasheets. Because the exact activity values on a per unit basis can largely fluctuate depending on a number of factors, including the nature of the assay, cell density, age of cells/passage number, culture media used, and end user technique, the specific activity is best defined as a range and we guarantee the specific activity of all our lots will be within the range indicated on the datasheet. Please note this only applies to recombinants labeled for use in bioassays. ELISA standard recombinant proteins are not recommended for bioassay usage as they are not tested for these applications.
- Have your recombinants been tested for stability?
-
Our testing shows that the recombinant proteins are able to withstand room temperature for a week without losing activity. In addition the recombinant proteins were also found to withstand four cycles of freeze and thaw without losing activity.
- Does specific activity of a recombinant protein vary between lots?
-
Specific activity will vary for each lot and for the type of experiment that is done to validate it, but all passed lots will have activity within the established ED50 range for the product and we guarantee that our products will have lot-to-lot consistency. Please conduct an experiment-specific validation to find the optimal ED50 for your system.
- How do you convert activity as an ED50 in ng/ml to a specific activity in Units/mg?
-
Use formula Specific activity (Units/mg) = 10^6/ ED50 (ng/mL)
Follow Us